HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 20% to New High as Xuan Yuening Enters National Reimbursement List and Two Oncology Products Approved Within the Year

Stock News12-12

XUANZHUBIO-B (02575) surged over 20%, hitting a record high of HK$93.05. At the time of writing, the stock was up 19.51% to HK$92.5, with a turnover of HK$18.78 million.

The rally follows the company's announcement that its innovative drug, Xuan Yuening, has been included in China's National Reimbursement Drug List (NRDL) for the first time. The successful NRDL negotiation is expected to enhance the affordability and accessibility of Xuan Yuening for patients, driving market expansion and sales growth, which will positively impact the company's long-term development.

Additionally, XUANZHUBIO-B has secured approvals for two oncology products this year, marking a critical milestone in its innovation-driven strategy. Piroxiclib, targeting differentiated indications in breast cancer, and Diloac, with high intracranial penetration and an IC-ORR exceeding 91%, address unmet needs in brain metastasis treatment. Together with Anaprazole Sodium, these drugs form a "troika" commercialization framework, laying a solid foundation for the company's sustained growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108401237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108401237","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 20% to New High as Xuan Yuening Enters National Reimbursement List and Two Oncology Products Approved Within the Year","media":"Stock News","content":"<p>XUANZHUBIO-B (02575) surged over 20%, hitting a record high of HK$93.05. At the time of writing, the stock was up 19.51% to HK$92.5, with a turnover of HK$18.78 million.</p>\n<p>The rally follows the company's announcement that its innovative drug, Xuan Yuening, has been included in China's National Reimbursement Drug List (NRDL) for the first time. The successful NRDL negotiation is expected to enhance the affordability and accessibility of Xuan Yuening for patients, driving market expansion and sales growth, which will positively impact the company's long-term development.</p>\n<p>Additionally, XUANZHUBIO-B has secured approvals for two oncology products this year, marking a critical milestone in its innovation-driven strategy. Piroxiclib, targeting differentiated indications in breast cancer, and Diloac, with high intracranial penetration and an IC-ORR exceeding 91%, address unmet needs in brain metastasis treatment. Together with Anaprazole Sodium, these drugs form a \"troika\" commercialization framework, laying a solid foundation for the company's sustained growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 20% to New High as Xuan Yuening Enters National Reimbursement List and Two Oncology Products Approved Within the Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | XUANZHUBIO-B (02575) Surges Over 20% to New High as Xuan Yuening Enters National Reimbursement List and Two Oncology Products Approved Within the Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XUANZHUBIO-B (02575) surged over 20%, hitting a record high of HK$93.05. At the time of writing, the stock was up 19.51% to HK$92.5, with a turnover of HK$18.78 million.</p>\n<p>The rally follows the company's announcement that its innovative drug, Xuan Yuening, has been included in China's National Reimbursement Drug List (NRDL) for the first time. The successful NRDL negotiation is expected to enhance the affordability and accessibility of Xuan Yuening for patients, driving market expansion and sales growth, which will positively impact the company's long-term development.</p>\n<p>Additionally, XUANZHUBIO-B has secured approvals for two oncology products this year, marking a critical milestone in its innovation-driven strategy. Piroxiclib, targeting differentiated indications in breast cancer, and Diloac, with high intracranial penetration and an IC-ORR exceeding 91%, address unmet needs in brain metastasis treatment. Together with Anaprazole Sodium, these drugs form a \"troika\" commercialization framework, laying a solid foundation for the company's sustained growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1108401237","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108401237","pubTimestamp":1765505655,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XUANZHUBIO-B (02575) surged over 20%, hitting a record high of HK$93.05. At the time of writing, the stock was up 19.51% to HK$92.5, with a turnover of HK$18.78 million. The rally follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02575":"轩竹生物-B"},"translate_title":"港股动向|轩竹生物-B(02575)大涨超20%创新高，宣悦宁进入国家报销名单，年内两款肿瘤产品获批","themeId":"7432cf6f68b776bebe5e689173bcab7f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"XUANZHUBIO-B (02575) surged over 20%, hitting a record high of HK$93.05. At the time of writing, the stock was up 19.51% to HK$92.5, with a turnover of HK$18.78 million.\nThe rally follows the company's announcement that its innovative drug, Xuan Yuening, has been included in China's National Reimbursement Drug List (NRDL) for the first time. The successful NRDL negotiation is expected to enhance the affordability and accessibility of Xuan Yuening for patients, driving market expansion and sales growth, which will positively impact the company's long-term development.\nAdditionally, XUANZHUBIO-B has secured approvals for two oncology products this year, marking a critical milestone in its innovation-driven strategy. Piroxiclib, targeting differentiated indications in breast cancer, and Diloac, with high intracranial penetration and an IC-ORR exceeding 91%, address unmet needs in brain metastasis treatment. Together with Anaprazole Sodium, these drugs form a \"troika\" commercialization framework, laying a solid foundation for the company's sustained growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108401237","isCrawlerRequest":true}